{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:22:09Z","timestamp":1788823329877,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03168-w","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T03:59:41Z","timestamp":1743220781000},"page":"2429-2444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mobility and Quality of Life in Adults with Paediatric-Onset Hypophosphatasia Treated with Asfotase Alfa: Results from UK Managed Access Agreement"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1944-8302","authenticated-orcid":false,"given":"Katie E.","family":"Moss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8216-3828","authenticated-orcid":false,"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7019-5647","authenticated-orcid":false,"given":"Shona","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Zygouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-0048","authenticated-orcid":false,"given":"Muhammad K.","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3629-2338","authenticated-orcid":false,"given":"Tarekegn","family":"Geberhiwot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9187-9967","authenticated-orcid":false,"given":"Kenneth E. S.","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Selby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7576-250X","authenticated-orcid":false,"given":"Judith S.","family":"Bubbear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"3168_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","volume":"102","author":"MP Whyte","year":"2017","unstructured":"Whyte MP. Hypophosphatasia: an overview for 2017. Bone. 2017;102:15\u201325.","journal-title":"Bone"},{"issue":"2","key":"3168_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.11138\/ccmbm\/2017.14.1.230","volume":"14","author":"F Conti","year":"2017","unstructured":"Conti F, Ciullini L, Pugliese G. Hypophosphatasia: clinical manifestation and burden of disease in adult patients. Clin Cases Miner Bone Metab. 2017;14(2):230\u20134.","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"12","key":"3168_CR3","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s00198-021-06025-y","volume":"32","author":"L Seefried","year":"2021","unstructured":"Seefried L, Rak D, Petryk A, Genest F. Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa. Osteoporos Int. 2021;32(12):2505\u201313.","journal-title":"Osteoporos Int"},{"issue":"1","key":"3168_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2021.03.011","volume":"133","author":"PS Kishnani","year":"2021","unstructured":"Kishnani PS, Del Angel G, Zhou S, Rush ET. Investigation of ALPL variant states and clinical outcomes: an analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2021;133(1):113\u201321.","journal-title":"Mol Genet Metab"},{"issue":"7410","key":"3168_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(65)91422-4","volume":"2","author":"RG Russell","year":"1965","unstructured":"Russell RG. Excretion of inorganic pyrophosphate in hypophosphatasia. Lancet. 1965;2(7410):461\u20134.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"3168_CR6","first-page":"380","volume":"10","author":"C Rockman-Greenberg","year":"2013","unstructured":"Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013;10(Suppl 2):380\u20138.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"1","key":"3168_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13023-022-02393-8","volume":"17","author":"KM Dahir","year":"2022","unstructured":"Dahir KM, Seefried L, Kishnani PS, et al. Clinical profiles of treated and untreated adults with hypophosphatasia in the Global HPP Registry. Orphanet J Rare Dis. 2022;17(1):277.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3168_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1359\/jbmr.081253","volume":"24","author":"MP Whyte","year":"2009","unstructured":"Whyte MP. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res. 2009;24(6):1132\u20134.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"3168_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-226895","volume":"12","author":"N Khade","year":"2019","unstructured":"Khade N, Carrivick S, Orr C, Prentice D. Recurrent abducens nerve palsy and hypophosphatasia syndrome. BMJ Case Rep. 2019;12(4): e226895.","journal-title":"BMJ Case Rep"},{"key":"3168_CR10","doi-asserted-by":"publisher","first-page":"1138599","DOI":"10.3389\/fendo.2023.1138599","volume":"14","author":"KM Dahir","year":"2023","unstructured":"Dahir KM, Kishnani PS, Martos-Moreno GA, et al. Impact of muscular symptoms and\/or pain on disease characteristics, disability, and quality of life in adult patients with hypophosphatasia: a cross-sectional analysis from the Global HPP Registry. Front Endocrinol. 2023;14:1138599.","journal-title":"Front Endocrinol"},{"key":"3168_CR11","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.metabol.2016.07.006","volume":"65","author":"TJ Weber","year":"2016","unstructured":"Weber TJ, Sawyer EK, Moseley S, Odrljin T, Kishnani PS. Burden of disease in adult patients with hypophosphatasia: results from two patient-reported surveys. Metabolism. 2016;65:1522\u201330.","journal-title":"Metabolism"},{"issue":"11","key":"3168_CR12","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1002\/jbmr.4130","volume":"35","author":"L Seefried","year":"2020","unstructured":"Seefried L, Dahir K, Petryk A, et al. Burden of illness in adults with hypophosphatasia: data from the Global Hypophosphatasia Patient Registry. J Bone Miner Res. 2020;35(11):2171\u20138.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"3168_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12891-019-2420-8","volume":"20","author":"W H\u00f6gler","year":"2019","unstructured":"H\u00f6gler W, Langman C, da Silva HG, et al. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskelet Disord. 2019;20(1):80.","journal-title":"BMC Musculoskelet Disord"},{"key":"3168_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","volume":"121","author":"PS Kishnani","year":"2019","unstructured":"Kishnani PS, Rockman-Greenberg C, Rauch F, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019;121:149\u201362.","journal-title":"Bone"},{"key":"3168_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115664","volume":"142","author":"L Seefried","year":"2021","unstructured":"Seefried L, Kishnani PS, Moseley S, et al. Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia. Bone. 2021;142: 115664.","journal-title":"Bone"},{"key":"3168_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116856","volume":"175","author":"L Seefried","year":"2023","unstructured":"Seefried L, Genest F, Petryk A, Veith M. Effects of asfotase alfa in adults with pediatric-onset hypophosphatasia over 24 months of treatment. Bone. 2023;175: 116856.","journal-title":"Bone"},{"issue":"9","key":"3168_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10395","volume":"4","author":"F Genest","year":"2020","unstructured":"Genest F, Rak D, Petryk A, Seefried L. Physical function and health-related quality of life in adults treated with asfotase alfa for pediatric-onset hypophosphatasia. JBMR Plus. 2020;4(9): e10395.","journal-title":"JBMR Plus"},{"issue":"1","key":"3168_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-024-03048-6","volume":"19","author":"PS Kishnani","year":"2024","unstructured":"Kishnani PS, Martos-Moreno G\u00c1, Linglart A, et al. Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry. Orphanet J Rare Dis. 2024;19(1):109.","journal-title":"Orphanet J Rare Dis"},{"key":"3168_CR19","doi-asserted-by":"crossref","unstructured":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111\u20137.","DOI":"10.1164\/ajrccm.166.1.at1102"},{"issue":"3","key":"3168_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1067\/mpd.2000.107892","volume":"137","author":"RH Engelbert","year":"2000","unstructured":"Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs H, Helders PJ. Osteogenesis imperfecta in childhood: prognosis for walking. J Pediatr. 2000;137(3):397\u2013402.","journal-title":"J Pediatr"},{"key":"3168_CR21","volume-title":"The brief pain inventory user guide","author":"CS Cleeland","year":"2009","unstructured":"Cleeland CS. The brief pain inventory user guide. Houston, TX: The University of Texas M. D. Anderson Cancer Center; 2009."},{"key":"3168_CR22","volume-title":"EQ-5D-3L user guide","author":"M Van Reenen","year":"2015","unstructured":"Van Reenen M, Oppe M. EQ-5D-3L user guide. Rotterdam: EuroQol Research Foundation; 2015."},{"key":"3168_CR23","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00198-023-06749-z","volume":"34","author":"MA Rauf","year":"2023","unstructured":"Rauf MA, Kotecha J, Moss K. Reducing diagnostic delay in hypophosphatasia: a case series of 14 patients presenting to general rheumatology. Osteoporos Int. 2023;34:1647\u201352.","journal-title":"Osteoporos Int"},{"key":"3168_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00003086-198109000-00015","volume":"159","author":"EE Bleck","year":"1981","unstructured":"Bleck EE. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop Relat Res. 1981;159:111\u201322.","journal-title":"Clin Orthop Relat Res"},{"issue":"6","key":"3168_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10131","volume":"3","author":"D Phillips","year":"2019","unstructured":"Phillips D, Tomazos IC, Moseley S, et al. Reliability and validity of the 6-minute walk test in hypophosphatasia. JBMR Plus. 2019;3(6): e10131.","journal-title":"JBMR Plus"},{"issue":"1","key":"3168_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13023-021-01722-7","volume":"16","author":"EI Pierpont","year":"2021","unstructured":"Pierpont EI, Simmons JH, Spurlock KJ, Shanley R, Sarafoglou KM. Impact of pediatric hypophosphatasia on behavioral health and quality of life. Orphanet J Rare Dis. 2021;16(1):80.","journal-title":"Orphanet J Rare Dis"},{"key":"3168_CR27","unstructured":"Asfotase alfa for treating paediatric-onset hypophosphatasia. Highly specialised technologies guidance. National Institute for Health and Care Excellence, 2023. Available at: www.nice.org.uk\/guidance\/hst23. Accessed 5 Jan 2024."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03168-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03168-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03168-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:50:45Z","timestamp":1744872645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03168-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3168"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03168-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Katie E. Moss reports support for advisory board participation\/presentations from Alexion, AstraZeneca Rare Disease and receipt of educational grants from AbbVie; Amgen; Alexion, AstraZeneca Rare Disease; Novartis; and UCB. Richard Keen reports support for advisory board participation\/presentations from Alexion, AstraZeneca Rare Disease. Alexandros Zygouras and Shona Fang are employees of Alexion, AstraZeneca Rare Disease and may own stock\/options with AstraZeneca. Muhammad Javaid reports speaker honoraria and grants from Amgen, Kyowa Kirin, UCB, AbbVie, Besins Healthcare, and Sanofi. Tarekegn Geberhiwot and Peter Selby report no conflicts. Judith S. Bubbear reports support for speaker\/consultancy participation from Alexion, AstraZeneca Rare Disease. Kenneth E.S. Poole reports support from the Cambridge NIHR Biomedical Research Centre. Jennifer S. Walsh reports speaker's honoraria from Eli Lilly, drug donation for clinical studies from Eli Lilly, and consulting fees from Mereo BioPharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This analysis used prospective data collected from participants enrolled in the MAA for asfotase alfa between November 20, 2017, and February 2, 2023. The project complied with all relevant data protection and privacy regulations, including the European Data Protection Act and\/or institution\/country-specific participant privacy requirements and was performed in accordance with the Declaration of Helsinki. All participants were informed of the use and disclosure of their data. All patients consented to participate in the MAA, including attending regular appointments and completing questionnaires, and to have their data entered into the MAA database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}